Table 2.
Parameter estimates of the final rifampicin pharmacokinetic model
| Parameter | Typical value [RSE (%)]a | IIVb [RSE (%)]a | IOVc [RSE (%)]a |
|---|---|---|---|
| CLstd (L/h) | 8.15 (9.00) | 32.6 (27.7) | 25.1 (20.0) |
| Vc.std (L) | 16.2 (10.2) | 43.4 (19.8) | |
| MTT (h) | 1.04 (6.10) | 40.6 (8.60) | |
| NN | 8.04 (11.9) | ||
| F (%) | 1 (fixed) | 48.1 (12.7) | |
| TM50 (weeks) | 58.2 (9.00) | ||
| Hill | 2.21 (11.7) | ||
| Additive error, Cohort 1 (mg/L) | 0.122 (24.6) | ||
| Additive error, Cohort 2 (mg/L) | 0.630 (30.3) | ||
| Proportional error (%) | 23.4 (4.50) |
CLstd and Vc.std, oral clearance and apparent volume of distribution, respectively (the values reported refer to a 12.5 kg child and for CL at full maturation); MTT, absorption mean transit time (value at full maturation); NN, number of transit compartments; F, relative bioavailability; TM50, post-menstrual age at which 50% of clearance and mean transit time maturation is achieved; Hill, steepness of the maturation function.
aRSE, relative standard error reported on the approximate standard deviation scale.
bIIV, inter-individual variability expressed as percentage coefficient of variation (%CV).
cIOV, inter-occasional variability expressed as percentage coefficient of variation (%CV).